Quest Diagnostics is a leading global provider of diagnostic information services, specializing in laboratory testing and related services
The company offers a comprehensive range of medical testing, including routine blood work, genetic testing, and specialized diagnostic imaging, aimed at helping healthcare providers make informed decisions about patient care. With a vast network of laboratories and patient service centers, Quest Diagnostics plays a critical role in the healthcare ecosystem by delivering accurate and timely results, contributing to enhanced patient outcomes and supporting public health initiatives. Through their innovative technologies and dedication to quality, the company strives to advance the practice of medicine and improve overall health management.
BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSEDGX) company, and Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced a research collaboration. Lisata will deploy the highly sensitive Haystack MRD™ technology for the detection of circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for metastatic pancreatic cancer.
Intelligent Bio Solutions Inc. (NASDAQINBS) is a medical technology firm at the forefront of developing and marketing rapid, intelligent, cutting-edge, and non-intrusive drug testing and health screening solutions. The company is actively involved in commercializing its smart fingerprinting device for drug testing, which has gained rapid traction in the healthcare market segment.
Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics (NYSEDGX), the nation’s leading provider of diagnostic information services, today announced a collaboration involving Ultima’s next generation sequencing (NGS) technology in oncology and other clinical areas.
Quest Diagnostics Incorporated (NYSEDGX) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 1.35% on the day to $129.41.
With the mainstream popularity of ChatGPT, artificial intelligence (AI) has been all the rage in 2023. The AI wars between Microsoft Co. (NASDAQMSFT) invest
Quest Diagnostics Incorporated (NYSEDGX) has caught the attention of the investment community today with its bullish price action. The company’s shares are currently up 3.4% on the day to $140.
DermTech, Inc. (NASDAQDMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today an agreement with Sonora Quest Laboratories (Sonora Quest), Arizona’s leading diagnostic laboratory, to expand access to enhanced melanoma detection. As a result of the agreement, Sonora Quest will be the exclusive laboratory in Arizona to offer the DermTech Melanoma Test to its vast network of healthcare providers.
Achievers, an industry-leading employee experience software platform, announces its joint win of a Gold award by Brandon Hall Group with its customer case study of Quest Diagnostics (NYSEDGX), the world's leading provider of diagnostic information services.
San Diego, CA -- (SBWIRE) -- 05/12/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Quest Diagnostics Incorporated.
San Diego, CA -- (SBWIRE) -- 03/23/2022 -- Quest Diagnostics Incorporated was under investigation over potential securities laws violations in connection with certain financial statements.
Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years. Growing medical spending by the government and regulatory bodies is expected to drive the market during the forecast period. Government and key […]
